Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.81 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.73 |
| ▸ | GSK3A | P49840 | 3/20 | 0.73 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.73 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.73 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.73 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.73 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.73 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.73 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.73 |
| ▸ | CLK2 | P49760 | 2/20 | 0.73 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.73 |
| ▸ | EEF2K | O00418 | 1/20 | 0.73 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.73 |
| ▸ | STK3 | Q13188 | 1/20 | 0.73 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.73 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.73 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.73 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.69 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4660981 | 1.00 | AKT1 (0.81) | AKT1PIM2GSK3ARPS6KA3PRKCD | |
| SCHEMBL4659556 | 0.92 | AKT1 (0.85) | AKT1PIM2GSK3ARPS6KA3PRKCD | |
| SCHEMBL4659553 | 0.92 | AKT1 (0.85) | AKT1PIM2GSK3ARPS6KA3PRKCD | |
| SCHEMBL7128961 | 0.90 | AKT1 (1.00) | AKT1PIM2GSK3ARPS6KA3PRKCD | |
| SCHEMBL6857809 | 0.90 | AKT1 (1.00) | AKT1PIM2GSK3ARPS6KA3PRKCD | |
| SCHEMBL6857813 | 0.90 | AKT1 (1.00) | AKT1PIM2GSK3ARPS6KA3PRKCD | |
| SCHEMBL6854791 | 0.85 | AKT1 (1.00) | AKT1PIM2GSK3ARPS6KA3PRKCD | |
| SCHEMBL6853377 | 0.84 | AKT1 (1.00) | AKT1PIM2GSK3ARPS6KA3PRKCD | |
| SCHEMBL6853380 | 0.84 | AKT1 (1.00) | AKT1PIM2GSK3ARPS6KA3PRKCD | |
| SCHEMBL6853331 | 0.83 | AKT1 (1.00) | AKT1PIM2GSK3ARPS6KA3PRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | claimed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | claimed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | claimed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | AKT1 1/4885PIM2 285/4885GSK3A 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.